Omeros Return on Tangible Equity 2010-2023 | OMER
Current and historical return on tangible equity values for Omeros (OMER) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Omeros Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2023-12-31 | $-0.12B | $-0.03B | -1275.68% |
| 2023-09-30 | $0.02B | $-0.01B | 54.05% |
| 2023-06-30 | $0.04B | $0.02B | 141.38% |
| 2023-03-31 | $0.05B | $0.06B | 303.23% |
| 2022-12-31 | $0.05B | $0.09B | 9600.00% |
| 2022-09-30 | $0.20B | $-0.05B | -1333.33% |
| 2022-06-30 | $0.19B | $-0.03B | -280.14% |
| 2022-03-31 | $0.20B | $-0.01B | -160.00% |
| 2021-12-31 | $0.19B | $0.02B | -109.76% |
| 2021-09-30 | $-0.12B | $-0.26B | 58.22% |
| 2021-06-30 | $-0.14B | $-0.25B | 82.25% |
| 2021-03-31 | $-0.14B | $-0.22B | 96.79% |
| 2020-12-31 | $-0.14B | $-0.12B | 109.38% |
| 2020-09-30 | $-0.13B | $-0.09B | 105.52% |
| 2020-06-30 | $-0.11B | $-0.16B | 78.97% |
| 2020-03-31 | $-0.09B | $-0.13B | 68.88% |
| 2019-12-31 | $-0.08B | $-0.11B | 66.40% |
| 2019-09-30 | $-0.08B | $-0.14B | 63.54% |
| 2019-06-30 | $-0.10B | $-0.13B | 91.82% |
| 2019-03-31 | $-0.12B | $-0.12B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $-0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $-0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.183B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $186.584B | 24.49 |
| Stryker (SYK) | United States | $127.690B | 31.66 |
| Boston Scientific (BSX) | United States | $107.347B | 34.19 |
| Medtronic (MDT) | Ireland | $105.881B | 14.99 |
| EssilorLuxottica (ESLOY) | France | $98.566B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.036B | 0.00 |
| Haleon (HLN) | United Kingdom | $38.584B | 30.18 |
| ResMed (RMD) | United States | $32.074B | 30.08 |
| Terumo (TRUMY) | Japan | $24.746B | 34.95 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.522B | 15.79 |
| Baxter (BAX) | United States | $20.379B | 14.86 |
| Koninklijke Philips (PHG) | Netherlands | $19.567B | 15.61 |
| Insulet (PODD) | United States | $11.637B | 61.10 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.689B | 0.00 |
| Demant (WILYY) | Denmark | $9.943B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.869B | 23.44 |
| BellRing Brands (BRBR) | United States | $7.379B | 39.68 |
| Haemonetics (HAE) | United States | $4.621B | 23.63 |
| Lantheus Holdings (LNTH) | United States | $4.494B | 11.60 |
| Perrigo (PRGO) | Ireland | $4.328B | 12.38 |
| GN Store Nord (GNNDY) | Denmark | $4.065B | 26.32 |
| Envista Holdings (NVST) | United States | $3.504B | 13.33 |
| Prestige Consumer Healthcare (PBH) | United States | $3.499B | 16.54 |
| QuidelOrtho (QDEL) | United States | $2.651B | 9.62 |
| Neogen (NEOG) | United States | $2.630B | 25.29 |
| Green Thumb Industries (GTBIF) | United States | $2.571B | 81.47 |
| ICU Medical (ICUI) | United States | $2.311B | 17.24 |
| TG Therapeutics (TGTX) | United States | $2.082B | 673.50 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.936B | 0.00 |
| Owens & Minor (OMI) | United States | $1.922B | 18.45 |
| Agios Pharmaceuticals (AGIO) | United States | $1.770B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.697B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.469B | 48.49 |
| InMode (INMD) | Israel | $1.439B | 7.45 |
| National Vision Holdings (EYE) | United States | $1.400B | 43.61 |
| AdaptHealth (AHCO) | United States | $1.324B | 9.96 |
| Warby Parker (WRBY) | United States | $1.271B | 0.00 |
| AtriCure (ATRC) | United States | $1.121B | 0.00 |
| MacroGenics (MGNX) | United States | $0.911B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.893B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.794B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.709B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.682B | 14.73 |
| Evolus (EOLS) | United States | $0.662B | 0.00 |
| Jin Medical (ZJYL) | China | $0.626B | 0.00 |
| Quanterix (QTRX) | United States | $0.595B | 0.00 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.516B | 11.17 |
| PetIQ (PETQ) | United States | $0.486B | 18.16 |
| TerrAscend (TSNDF) | Canada | $0.486B | 0.00 |
| ZimVie (ZIMV) | United States | $0.431B | 26.37 |
| Biote (BTMD) | United States | $0.411B | 3.91 |
| OraSure Technologies (OSUR) | United States | $0.407B | 6.73 |
| Surmodics (SRDX) | United States | $0.373B | 40.26 |
| Aurora Cannabis (ACB) | Canada | $0.365B | 0.00 |
| Zynex (ZYXI) | United States | $0.361B | 41.52 |
| Viemed Healthcare (VMD) | United States | $0.322B | 31.96 |
| Cerus (CERS) | United States | $0.310B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.279B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.250B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.237B | 14.65 |
| Organigram Holdings (OGI) | Canada | $0.192B | 0.00 |
| Veru (VERU) | United States | $0.186B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.183B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.170B | 0.00 |
| High Tide (HITI) | Canada | $0.161B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.156B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.144B | 72.36 |
| FitLife Brands (FTLF) | United States | $0.132B | 21.28 |
| Jushi Holdings (JUSHF) | United States | $0.131B | 0.00 |
| InterCure (INCR) | Israel | $0.121B | 20.46 |
| Fonar (FONR) | United States | $0.103B | 8.84 |
| MariMed (MRMD) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.100B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.098B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.092B | 0.00 |
| Safety Shot (SHOT) | United States | $0.082B | 0.00 |
| Chimerix (CMRX) | United States | $0.080B | 0.00 |
| Brainsway (BWAY) | Israel | $0.079B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.058B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.054B | 3.53 |
| Apyx Medical (APYX) | United States | $0.050B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.044B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.043B | 0.00 |
| ImmuCell (ICCC) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 14.77 |
| Bright Green (BGXX) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.035B | 0.00 |
| Exagen (XGN) | United States | $0.024B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.017B | 0.00 |
| Agape ATP (ATPC) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.010B | 71.82 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |